IAGIM
RESEARCH
|
||
THE INTERNATIONAL GLIMER I, II & III MS STUDY (Ongoing 2010 - 2025 | Fifteen Year GLIMER Project - Extended 2019) |
||
Prof. Jeremy D. Block - Neuro-Immuno-Epidemiologist (N.I.E.) Chief Scientist IAGIM Institute and CEO LIGroup |
ALTERNATIVE MORE ADVANCED MS Article - www.LocumUSA.com ; Ref: "Article of the Month" Prof. J. D. Block - Neuro-Immuno-Epidemiologist (N.I.E.) |
||
|
||
TO BE PUBLISHED - WATCH THIS SPACE! |
||
Jeremy
David Block
BSc. (Eng.), MSc.(WCU), (Micro/Stats UNISA), D.Pharm (Wits)., Ph.D. (Neuro IAGIM. U.) Part Ten - 2019/7 - Total Parts 20 - Pages 110) ALTERNATIVE MORE ADVANCED MS Article - www.LocumUSA.com ; Ref: "Article of the Month" Prof. J. D. Block - Neuro-Immuno-Epidemiologist (N.I.E.) Background: Prof. J. D. Block served for the duration of the development of COP 1 as a senior medical/pharmaceutical researcher and part of the Teva COP 1 innovative research team in the early nineties that rapidly developed Teva's first MS immuno-modulating drug Glatiramer Acetate (CopaxoneTM). As Chief Scientist as well as Teva Group Scientific Research Auditor, and by touching each and every part of Teva's overall scientific team Teva rapidly attained ND registration with the FDA under Dr. J. D. Block scientific and technical guidence and regulatory department training and overview. |
ALTERNATIVE
MORE ADVANCED MS Article - www.LocumUSA.com ; Ref: "Article
of the Month"
Prof.
J. D. Block - Neuro-Immuno-Epidemiologist
(N.I.E.)
Dictionary
of Cancer Terms
#
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
|
Shipping
| By FastTrack
| Data Protection |
|